Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmaceutical Economy In China Sees Steady Growth

This article was originally published in PharmAsia News

Executive Summary

According to recent statistics, total purchases of the top seven medical products in China were RMB 192.6 billion from January to June, an increase of 10.74 percent compared to the same period last year. Among them, pharmaceutical products accounted for RMB 147.2 billion, up 11.85 percent; and medical devices, in the amount of RMB 2.4 billion, increased 1.27 percent. The total sales were RMB 213.7 billion, 11.66 percent more than the same period last year. The areas that took the lead in sales were Shanghai, Beijing, Zhejiang, Guangdong, Jiangsu and Anhui. Total sales in these regions account for 62 percent of China's total sales. (Click here for more - Chinese lanugage)

You may also be interested in...



EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel